17 April 2023
Merck (NYSE: MRK) announced today that it had entered into a definitive merger agreement under which Merck will acquire Prometheus Biosciences, Inc. (NASDAQ: RXDX) for $200 per share in cash for a total equity value of approximately $10.8 billion.
Source: Company’s Press Release